Drilldown: Medicines

Other values:

Search

None (25) · Dalmane (1) · Doral (1) · Focalin, Focalin XR (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · MAO inhibitor; monoamine releasing agent (1) · MAO inhibitor; serotonin releasing agent (1) · Monoamine releasing agent (3) · Monoamine releasing agent; 5-HT2A agonist (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Serotonin releasing agent (2) · Serotonin releasing agent; 5-HT2A agonist (3) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3)

None (38) · ADHD, narcolepsy (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1)

None (40) · 0.25 mg (1)

None (40) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1)

None (40) · 10 mg/d (1)

None (38) · Oral (3) · transdermal (1)

None (38) · 20–60 min (oral) (1) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · 30–60 min (1)

None (38) · 6 h (immediate-release); ~11 h (extended-release) (1) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · IR 4–6 h; XR 8–12 h (1)

None (38) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2–3 h (parent compound) (1)

None (38) · 80-90% oral (1) · ~22–25% (1) · ~30% (high first-pass) (1)

None (38) · Category C (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)

None (38) · Schedule II (2) · Schedule IV (US) (1)